| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959982 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
| US10413525 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
| US9839626 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
| US11202772 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
Drizalma Sprinkle is owned by Sun Pharm.
Drizalma Sprinkle contains Duloxetine Hydrochloride.
Drizalma Sprinkle has a total of 4 drug patents out of which 0 drug patents have expired.
Drizalma Sprinkle was authorised for market use on 19 July, 2019.
Drizalma Sprinkle is available in capsule, delayed rel pellets;oral dosage forms.
The generics of Drizalma Sprinkle are possible to be released after 13 April, 2037.
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 July, 2019
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL
DRIZALMA SPRINKLE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic